Search 

Anavex™ Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.

ANAVEX™ 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg.  Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.

A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®).  The combined therapeutics, referred to as “ANAVEX™ PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

ANAVEX PLUS is believed to be a compelling commercial opportunity.  The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually.  Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.

Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.

Apollonia Health researches and develops innovative oral hygiene products that can safely and selectively eliminate cavity-causing bacteria.

Our company manufactures revolutionary oral healthcare products made only with naturally occurring ingredients. Because of this, our products can be used safely by children.

Starinse is the flagship oral health care product from Apollonia Health, Inc. Based in Ontario, Apollonia Health Inc. is an oral healthcare biotech company dedicated to researching, developing, and commercializing the most innovative oral hygiene products to improve the oral healthcare of children around the world.

Our name, Aptuit, is derived from the words aptitude and intuition, two natural attributes that define our unique approach to providing drug discovery, development and manufacturing support. The name communicates our aptitude for scientific knowledge as well as our intuitive understanding of the needs of the pharmaceutical and biotechnological community. We summon these attributes to clarify current challenges and anticipate those that are to come, always with the determination to find solutions.

Since Aptuit was founded in 2004, we have forged a robust expansion of our resources. We are living up to the promise of our name by the ongoing assembly of experienced and talented scientists, and we are supporting them every step of the way with the most advanced resources at state-of-the art facilities.

Our corporate tagline - Uncommon Expertise. Exceptional Results - reflects our success in harnessing unique and outstanding strengths in drug discovery and drug development to deliver the results that our clients demand.

• Drug Design & Discovery
• Preclinical Biosciences
• API Development & Manufacture
• Solid State Chemistry
• Solid & Oral Dosage Form Development & Manufacture
• Integrated Drug Discovery & Drug Development
• Aptuit INDiGO®
• Physical & Analytical Chemistry

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research.

Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company’s prospects as an investment in terms of value, expected growth and risks.

Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm’s underwriting business. Because we’re not a broker/dealer, we don’t have “inventory” of a stock that we have to move with a tainted recommendation.

In recent years, numerous academic studies have concluded that investors benefit from independent research. Here are some of the benefits:

The incentives to bias recommendations upward are stronger for brokerage analysts affiliated with Investment Banks, according to a Stanford Graduate School of Business study.

The use of Independent Research through the Global Settlement has pulled optimism out of the market & cleared up rating confusion for retail investors, according to a Washington University/Case Western Reserve University study.

Independent Research Provider BUY ratings statistically and significantly outperform Investment Bank BUYS, according to a study published by the University of California-Davis, University of Michigan and University of California Los Angeles.

Single cell research has been identified as essential to the discovery of effective new drugs. Our team at ARL Designs has developed the Nano-Droplet Array Plate, an entirely new approach that satisfies this unmet need for isolating and studying individual cells over time.  Key to the proven success of this technology is our unique surface structure which causes nano-droplets to self-align and entrap individual cells at precise locations in large, high-density arrays.  Low fabrication costs will help drive this technology into the rapidly expanding market for 3D cell culture.

Founded by current CEO Justin Andrew Marsh. Mr. Marsh, a former microchip engineer and automation control contractor for companies such as Motorola, Intel and Medtronic, developed the company as a majority investor. The company originally specialized in the importation of enzymes and other raw materials.  As a majority of today’s current pharmaceuticals are designed to mimic enzymes, the company strives to develop and discover new medicines through enzyme research and development.

In 2003 Justin Andrew Marsh bought out his minority investors and Arthur Andrew Medical was formed. With the collaboration of well-known enzymologists and best-in-class materials, Arthur Andrew Medical began to create finished products under its own brand-name. In 2003, Neprinol, the world’s most potent systemic enzyme was born. Arthur Andrew's mission is to be the leader in the development of systemic enzyme products in the enzyme-pharma and supplement industry. While other companies develop products based on market trends and fads, Arthur Andrew Medical only adopts products with ingredients that have extensive clinical research for safety and efficacy.

This year marks 10 years of progress since Autism Speaks first opened its doors in 2005. As we move into our 11th year our goal is to significantly enhance autism services in every  community and push to get the groundbreaking ABLE Act , now the law of the land, implemented in all 50 states. Our dedicated field teams will be the ones heading this effort.

Thanks to the passion and generosity of our community, Autism Speaks has helped advance our understanding and treatment of autism in ways almost unimaginable ten years ago. 

AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. AzurRx BioPharma, Inc. is a recently founded private biotechnology company formed to focus on the development of the early stage pharmaceutical assets of ProteaBio Europe. The company is headquartered in New York, NY, with scientific operations based in Langlade, France.

AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. AzurRx BioPharma, Inc. is a recently founded private biotechnology company formed to focus on the development of the early stage pharmaceutical assets of ProteaBio Europe. The company is headquartered in New York, NY, with scientific operations based in Langlade, France.